Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Saturday, 20 January 2018, 18:32 HKT/SGT
Share:
    

Source: Eisai
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
For Chronic Constipation

TOKYO, Jan 20, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd today announced that EA Pharma has obtained new drug approval for bile acid transporter inhibitor "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533) for chronic constipation (excluding structural disease-induced constipation) in Japan.

GOOFICE Tablet was jointly developed by EA Pharma and Mochida Pharmaceutical. After inclusion in the National Health Insurance drug price list, the two companies will respectively market the product under the same brand name in Japan. EA Pharma and Eisai concluded a co-promotion agreement and jointly provide proper use information of this product.

GOOFICE Tablet, which EA Pharma in-licensed from Albireo AB, is a once-daily, orally available constipation treatment with a novel mechanism of action. GOOFICE Tablet inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon, which is expected to enhance natural defecation.

Constipation is a very common disease, and the prevalence is particularly high in women and the elderly. In constipation, symptoms such as sensation of incomplete evacuation and hard stools appear in addition to reduction of bowel movement frequency. When such symptoms become chronic, many patients suffer from decline of QOL (quality of life).

The above new drug approval was mainly based on the results of a placebo-controlled, double-blind Phase III clinical study in patients with chronic constipation conducted in Japan. As a result of oral administration of GOOFICE Tablet or placebo once daily for 14 days, statistically significant improvements were observed in the GOOFICE Tablet group as compared to the placebo group in the primary endpoint of spontaneous bowel movement(1)) frequency change and also in the secondary endpoints including complete spontaneous bowel movement(2)) frequency change and stool consistency. There were no serious adverse events in the study.

By providing GOOFICE Tablet with its novel mechanism of action, EA Pharma, Eisai and Mochida Pharmaceutical strive to broaden treatment options for patients with chronic constipation to make a further contribution to improve patients' QOL.

(1) defecation without use of laxative, enema or manual disimpaction
(2) spontaneous defecation without sensation of incomplete evacuation


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: